Active, not recruitingPhase 2NCT01821781

Immune Disorder HSCT Protocol

Studying OBSOLETE: Other complex syndrome of primary immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Washington University School of Medicine
Intervention
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan(drug)
Enrollment
20 enrolled
Eligibility
21 years · All sexes
Timeline
20132025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01821781 on ClinicalTrials.gov

Other trials for OBSOLETE: Other complex syndrome of primary immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Other complex syndrome of primary immunodeficiency

← Back to all trials